Early Markers of Disease and Response to Therapy

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

May 24, 2024

Study Completion Date

May 24, 2024

Conditions
Type 1 Diabetes
Interventions
DRUG

Abatacept

Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to \<50 kg receive 87.5 mg (0.7 mL), and \> 50 kg receive 125 mg (1.0 mL) per dose.

Trial Locations (2)

53226

Medical College of Wisconsin, Milwaukee

98101

Benaroya Research Institute, Seattle

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

Medical College of Wisconsin

OTHER

lead

Sandra Lord, MD

OTHER